INTRODUCTION
Lipopolysaccharide (LPS) is the structural component of the outer membrane of Gram-negative bacteria. In response to LPS, monocytes rapidly produce large amounts of various pro-inflammatory mediators, such as TNF-a, IL-1, IL-6, IL-8, along with tissue factor (TF), all of which contribute critically in the pathogenesis of sepsis.
LPS present in the circulation is instantly recognized by a specific plasma protein, LPS-binding protein (LBP). Hence, under non-saturating conditions, all of the LPS will circulate as a LPS-LBP complex, which is a ligand for the membrane receptors CD14 and Toll-like receptor 4 (TLR4) present on cells of the monocyte/macrophage lineage. Upon ligand binding, TLR4 mediates the LPS signal which is transduced in the cell in a complex process involving several parallel and partly overlapping phosphorylation cascades. The NF-kB pathway and three different mitogen-activated protein kinase (MAPK) pathways, p38, 1 c-Jun terminal kinase (JNK), 2 and p42/44 (ERK), 3, 4 all may become stimulated or activated upon LPS stimulation.
LPS-induced stimulation of the different phosphorylation cascades eventually leads to the activation of the transcription factors Egr-1, AP-1, as well as NF-kB, all of which are important for the expression of pro-inflammatory mediators such as TF. [4] [5] [6] TF is a cellular transmembrane receptor protein serving a role as a cofactor for coagulation factor VIIa (FVIIa). The TF/FVIIa complex, formed directly or by activation of a preformed TF/FVII complex, catalyzes limited cleavage and activation of FIX and FX. Such cleavage does not run rampant under normal conditions because of the general unavailability of exposed TF in the circulation. However, under various pathological condi-tions, such as chronic inflammation, cancer, thrombosis, coronary disease, wound repair, endocarditis, and Gramnegative sepsis, typically enhanced TF expression on circulating monocytes is observed. 7 When stimulating monocytes in vitro using inflammatory and immunomodulatory mediators such as LPS and immune complexes, TF expression is evident both at the transcriptional and translational levels, and TF is eventually exposed on the cell surface. 8, 9 Based on inhibition studies, it has been suggested that additional signaling pathways, involving protein kinase C (PKC), protein tyrosine kinases (PTK) and phospholipase A 2 (PLA 2 ), must be invoked in order to explain fully the regulation of monocyte TF. [10] [11] [12] [13] [14] Several studies have indicated that lipid mediators (eicosanoids and platelet activating factor [PAF]) may modulate the monocyte TF expression. In a recent report, PAF was shown to cause an increase in prior-expressed TF on the monocyte surface. 15 TF expression induced in isolated mononuclear cells was enhanced by added arachidonic acid (AA). 16 This enhancement was down-regulated by the presence of indomethacin, a cyclooxygenase (COX; COX-1 and COX-2) inhibitor, and blocked by the thromboxane A 2 prostanoid receptor (TP/TxA 2 ) antagonist SQ-29548. Abrogation of the release of AA by inhibitors of PLA 2 has also been shown to inhibit TF synthesis in LPSstimulated monocytes. 14, 17 Furthermore, 12-hydroxyeicosatetraenoic acid (12-HETE) has been reported to amplify monocyte TF in the presence of LPS or Pselectin. 18, 19 The TP receptor antagonists BMS-180291 and SQ-30741 were shown to decrease experimental aspirinresistant arterial and venous thrombosis in rats. 20, 21 In order to investigate further some of the claims that particular pathways and mediators may be involved in regulating LPS-induced TF and TNF-a, several enzyme inhibitors and receptor antagonists (RA) were tested alone or presented together using a whole blood ex vivo system. Thus, we explored the effects of blocking the receptors for PAF, TxA 2 , leukotriene B 4 (LTB 4 ) and serotonin, inhibiting the 14 kDa and 85 kDa PLA 2 enzymes mandatory for eicosanoid and PAF biosynthesis, inhibiting serine proteases and protein kinases, removing ADP and neutralizing the platelet fibronectin/fibrinogen receptor. Starting with full spectrum inhibition, a systematic elimination approach was adopted in an attempt to identify pathways that might contribute crucially in the events leading to the expression of TF and/or TNF-a in an ex vivo whole blood system stimulated with LPS.
MATERIALS AND METHODS

Materials
Escherichia coli serotype O26:B6 LPS was obtained from Difco (Detroit, MI, USA). Saline was sterile 0.9% NaCl from Pharmacia & Upjohn (Stockholm, Sweden). Lymphoprep was purchased from Nycomed (Oslo, Norway). The chromogenic thrombin peptide substrate Pefachrome TH (Pefa-5114) for determination of thrombin was obtained from Pentapharm Ltd (Basel, Switzerland). Staurosporine, bis-indolylmaleimide-HCl (BIM; GF-109203), cyproheptadine, creatine phosphate/creatine phosphokinase (CP/CPK), bovine serum albumin (BSA) and DMSO were purchased from Sigma Chemical Company (St Louis, MO, USA). Pefabloc SC (AEBSF) was from Fluka Chemie (Buchs, Switzerland), SQ-29548 (S-144) from RBI (Natick, MA, USA), and the peptide H-Arg-Gly-Asp-Ser-OH (RGDS) was from Calbiochem-Novabiochem (Läufelfingen, Switzerland). Arachidonyltrifluoromethyl ketone (AACOCF 3 ) was from Cayman Chemical Company (Ann Arbor, MI, USA) and BN-52021 (Ginkolide B) was bought from BIOMOL (Plymouth Meeting, PA, USA). SC-41930 was kindly provided by Searle (Skokie, IL, USA) and SB-203347 by SmithKline Beecham Pharmaceuticals (King of Prussia, PA, USA). Cephalin and rabbit brain TF were generously provided by T. Jansson, Nycomed (Oslo, Norway).
Inhibitor cocktail
The solitary effect of every inhibitor in the inhibitor cocktail was tested over a broad concentration range (see Table 1 ). Maximum concentrations of every inhibitor without cytotoxic or lysing effect on the blood cells were combined in the cocktail comprising all the compounds ( Table 1 & Fig. 1A ).
Blood sampling
Venous blood was drawn from healthy volunteers abstaining from any medication for 10 days before the experiment using a plastic syringe with a 19G needle. The blood samples were immediately aliquoted into polycarbonate tubes containing Fragmin (15 IE/ml blood; Pharmacia & Upjohn).
In vitro stimulation of whole blood
Aliquots of anticoagulated blood (1 ml) were placed in polycarbonate tubes and pre-incubated for 15 min with different pharmacological agents (literature-based concentrations as indicated in Table 1 were generally used) before stimulation with LPS (5 ng/ml). After 2 h incubation at 37°C in a rotary incubator (190 rpm), incubation was terminated by adding 100 ml of 5.0 mmol/l disodium EDTA (EDTA).
Isolation of mononuclear cells and plasma
After stimulation, blood aliquots were left with EDTA for 15 min to dissolve cellular aggregates. 22 The samples were diluted 1:1 with saline, and mononuclear cells were isolated by centrifugation (room temperature) at 420 g on top of Lymphoprep. The cells were washed with saline, frozen at -20°C and tested for TF activity after thawing. For the TNF-a assay, blood samples were centrifuged at 1600 g for 10 min and the plasma obtained stored frozen at -70°C until testing. Cell numbers were detected using a Sysmex™ K-1000 (TOA Medical Electronics Co., Ltd, Kobe, Japan). The mononuclear cells isolated at the end of the stimulation/inhibition period had a viability of approximately 95% as shown by trypan blue exclusion.
Assay for determination of tissue factor activity
TF activity of frozen and thawed mononuclear cells was measured using a two-stage amidolytic assay based on the ability of TF to accelerate the activation of FX by FVIIa 23 in the presence of bovine factor V and barium citrate (BaCi) eluate (containing coagulation factors VII, X and prothrombin). TF standards and lysed mononuclear cell samples were diluted in TBS-BSA buffer (0.025 mol/l Tris-HCl, 0.075 mol/l NaCl, 1.0 mg/ml BSA, pH 7.5). The chromogenic thrombin substrate TH, dissolved in sterile water at a concentration of 2.5 mmol/l, was mixed 1:1 with 0.1 mol/l Tris-HCl, pH 9.5. A 100 ml aliquot of pre-incubation mixture (10 ml cephalin, 3.0 U bovine FV, 200 ml BaCi eluate [prothrombin, 1.7 U; FX, 0.8 U; FVII, 0.5 U], 4 ml 50%
Regulation of endotoxin-induced monocyte tissue factor activity in human whole blood 287 (pg/ml plasma) a Fig. 1 . Inhibition of LPS-stimulated whole blood TF activity and TNF-a production. Whole blood aliquots (1 ml) were pre-incubated with the indicated inhibitor combinations prior to stimulation with LPS (5.0 ng/ml).
The aliquots were incubated at 37°C for 120 min in a rotary incubator. (A) The incubations were stopped with 100 ml of 5 mmol/l EDTA, mononuclear cells were isolated, frozen and thawed, and TF activity was assayed as described by Engstad et al. 22 (B) The incubations were stopped with 100 ml of 5 mmol/l EDTA, plasma was isolated, frozen at -70°C and tested for TNF-a by ELISA. Columns represent mean ± SEM (A, n = 6; B, n = 5). The asterisks indicate statistical significance (P < 0.05; difference from *LPS-stimulated blood and **LPS-stimulated blood pre-incubated with the reference inhibitor cocktail, respectively) using the Wilcoxon's signed rank test.
Staurosporine
Staurosporine TBS-BSA buffer) was mixed with 25 ml lysed diluted mononuclear cell sample or TF standard. After addition of 25 ml of 50 mmol/l CaCl 2 , the mixture was incubated at 37°C for 3 min. Then 50 ml of the diluted substrate solution was added and, after 3 min, the reaction was stopped by adding 200 ml of 50% acetic acid. The amount of colored product para-nitroanilide dihydroacetate generated was in direct proportion to the TF activity and was determined spectrophotometrically at 405 nm using a microplate reader. Crude rabbit brain extract was used as a standard for the TF activity, arbitrarily assigned as having an activity of 1000 mU/ml when undiluted. Fig. 2B] ). The sensitivity of the kits was < 5 pg/ml and 1 pg/ml, respectively.
Measurement of TNF-a
Statistical analysis
All results are reported as mean ± SEM. Differences between results obtained under the different conditions (i.e. after vehicle only, LPS-stimulation, or LPS-stimulation and inhibition) were tested using the Wilcoxon's signed rank test (SPSS 9.01 for Windows; SPSS Inc, Chicago, IL, USA). Significance was considered to be achieved when the P values were less than 0.05.
RESULTS
Effect of an inhibitor cocktail on TF and TNF-a activities
Neither of the pharmacological agents (inhibitors or receptor antagonists) listed in Table 1 significantly affected LPS-induced monocyte TF activity when added alone, according to dose-response testing (data not shown). When added as a cocktail comprising all the agents (see Fig. 1A ), the TF activity was reduced by approximately 77% (P < 0.05), corresponding to a drop from 40.1 ± 1.2 mU/10 6 monocytes (LPS + vehicle) to 9.3 ± 0.6 mU/10 6 monocytes (LPS + cocktail). Correspondingly, TNF-a as tested in the plasma samples was inhibited 49.1% by the cocktail, corresponding to a drop from 1179 ± 84 pg/ml plasma (LPS + vehicle) to 600 ± 84 pg/ml plasma (LPS + cocktail) as shown in Figure 1B .
Effect of eliminating the inhibitors one at a time
When similarly testing a series of incomplete cocktails, each lacking a single one of the different pharmacological agents, only three of these cocktails were significantly less efficient than the complete reference cocktail in inhibiting TF activity. The three agents thus singled out as responsible for the inhibitory activity of the cocktail, were the TP/TxA 2 receptor antagonist (RA) SQ-29548, the PAF RA BN-52021 and the protease inhibitor Pefabloc SC, which by their removal elevated the TF activity to 18.4 ± 2.3 mU/10 6 monocytes, 19.2 ± 3.1 mU/10 6 monocytes, and 11.4 ± 0.8 mU/10 6 monocytes, respectively, as compared to 9.3 ± 0.6 mU/10 6 monocytes (LPS + complete cocktail).
In contrast, protease inhibitor deletion led to no significant loss of cocktail inhibitory potential vis-a-vis plasma TNF-a (497 ± 109 pg/ml), whereas deletion of TP RA (908 ± 140 pg/ml) or PAF RA (824 ± 114) was proven effective also in relation to this parameter (Fig.  1B) . Furthermore, deletion of the LTB 4 RA SC-41930 significantly enhanced the TNF-a plasma concentration (803 ± 111 pg/ml; P < 0.05 compared to the complete inhibitor cocktail, 600 ± 84 pg/ml).
Removal of pharmacological agents
Based on the results shown in Figure 1 , the three agents TP RA, PAF RA and the protease inhibitor were singled out for further studies, testing cocktails from which two or all three of these agents had been deleted; the results are shown in Figure 2 . When all three agents had been deleted, monocyte TF activity (40.6 ± 4.5 mU/10 6 monocytes) was no different from that observed in the LPS-stimulated samples that had vehicle-only added (39.9 ± 9.8 mU/10 6 monocytes). When different combinations of agents in pairs (TP RA + PAF RA, TP RA + protease inhibitor, or PAF RA + protease inhibitor) were deleted, monocyte TF in the inhibited samples was restored to an intermediate level (26.9 ± 10.6 mU/10 6 monocytes, 28.7 ± 7.3 mU/10 6 monocytes, 24.0 ± 7.5 mU/10 6 monocytes, respectively).
Similar trends were observed when testing for TNF-a using cocktails where two or three agents had been deleted (Fig. 2B) . Worthy of notice is the observation that only the combinations incorporating TP RA removal led to significant restoration of LPS-induced plasma TNF-a. Elimination of the TxA 2 RA elevated plasma TNF-a from 1430 ± 310 pg/ml (LPS + complete cocktail) to 2340 ± 450 pg/ml and deletion of TxA 2 RA + PAF RA or TxA 2 RA + protease inhibitor in pairs elevated plasma to 2550 ± 380 pg/ml and 3050 ± 870 pg/ml, respectively.
As a control, the three agents singled out by the cocktail deletion studies were then assessed for their inhibitory potential by testing the three combined as a substitute for the complete cocktail. Thus samples were preincubated with PAF RA, TxA 2 RA and protease inhibitor combined. As shown in Figure 2A , this mixture inhibited the LPS-induced TF activity from 39.9 ± 9.8 mU/10 6 monocytes to 13.3 ± 4.6 mU/10 6 monocytes (66.7%; P < 0.05). Correspondingly, TNF-a was reduced from 3380 ± 490 pg/ml to 2040 ± 530 pg/ml (39.7%; P < 0.05) as shown in Figure 2B .
DISCUSSION
The aim of the present work was to characterize further the biochemical events leading to monocyte TF expression and TNF-a production, using human whole blood as a model system. Different known or putative steps of the LPSinduced signaling cascades were investigated using an inhibitor elimination approach. An inhibitor cocktail comprising an array of inhibitors was used as a reference for maximal inhibition, and the effects of individual agents were then screened by testing all possible cocktails where a single agent had been deleted. The inhibitory agents singled out by this method were then deleted from the inhibitory cocktail, in combinations of two or three, to investigate to what degree activity could be restored.
Thus it could be demonstrated that the receptors for TxA 2 and PAF are both involved in LPS-induced signaling leading to TF expression. PAF is known to evoke both inflammation and thrombosis, and PAF as well as TxA 2 are known as inducers of platelet aggregation. 24, 25 Stimulation of peripheral blood by LPS leads to activation of PLA 2 by phosphorylation and hence rapid release of PAF and AA from membrane phospholipids. 26, 27 In platelets, TxA 2 is the major cyclooxygenase product of AA metabolism. However, TxA 2 is probably not the only important mediator of activating the thromboxane receptor since ingestion of aspirin (ASA) is associated with enhanced LPS-induced TF in whole blood in vitro as well as in vivo. [28] [29] [30] However, ingestion of ASA inhibits the COX pathway and consequently diverts AA metabolites to the lipoxygenase pathways. Lorenzet and colleagues showed that 12-HETE released from platelets after ASA treatment is an important factor in promoting TF activity on the monocyte. 18 COX inhibition also leads to a decrease in the levels of the antiinflammatory prostaglandin E 2 (PGE 2 ).
Cayatte and colleagues recently reported that a TP receptor antagonist, S 18886, retarded the development of atherosclerotic lesions and decreased the serum levels of ICAM-1 in apolipoprotein E-deficient mice. 31 In contrast, neither of these parameters were affected by aspirin. Thus, the protective effect of ASA on myocardial infarction is probably not associated with the early events of lesion formation in the early phase of atherogenesis, but is important in preventing thrombosis formation through its anti-platelet aggregating effect at the late stages of arterial occlusion.
The PAF receptor plays a fundamental role in endotoxemic responses. This has been demonstrated in experiments where rats or mice were treated with PAF 290 Eilertsen, Østerud Table 1 . The aliquots were incubated at 37°C for 120 min in a rotary incubator. (A) The incubations were stopped with 100 ml of 5 mmol/l EDTA, mononuclear cells were isolated, frozen and thawed, and TF activity was assayed as described by Engstad et al. 22 
(B)
The incubations were stopped with 100 ml of 5 mmol/l EDTA, plasma was isolated, frozen at -70°C and tested for TNF-a by ELISA. Values represent mean ± SEM (A, n = 8; B, n = 7). The asterisks indicate statistical significance (P < 0.05; difference from *LPS stimulated controls and **LPS-stimulated blood pre-incubated with the reference inhibitor cocktail, respectively) using the Wilcoxon's signed rank test.
receptor antagonists (TCV-309, UR-12633, or WEB-2086) prior to infusion with endotoxin. Furthermore, PAF has been shown to prime monocytes for LPSinduced TF expression and to enhance the TF-inducing effect of LPS in a platelet/granulocyte-dependent reaction. 32, 33 These effects may be related to AA liberated in response to PAF. 34 Transgenic mice overexpressing the PAFR are hyper-responsive to endotoxin. 35 On the other hand, experiments using PAFR knockout mice suggest that the PAFR may not be an essential component of endotoxemic shock, but rather has a role as an amplifying factor. 36 Like infusion of AA and U-46619, intravascular administration of PAF induces shock and sudden death in wild-type mice. 37 PAF and TP antagonists are potent antiplatelet agents, and thus the results presented in this report are in line with the emerging notion that platelets play an important role in the expression of monocyte TF. 18, 38 In addition to serving as a source of phospholipids and several other factors needed for TF activity, platelets contribute to the monocyte TF activity by release of 12-HETE, platelet derived growth factor (PDGF) and platelet factor 4 (PF4), and via expression of P-selectin. 7, 39 Since platelets have no effect on LPS-induced TNF-a in whole blood, 38 this may account for the rather modest effect of the PAF and TP antagonists on TNF-a production seen in the present study.
Our experiments lend further support to the notion that proteases are involved in the regulation of monocyte TF. The protease inhibitor Pefabloc SC could have interfered with any number of key steps directly involved in the regulation of TF expression, e.g. at the level of gene transcription by inhibiting proteolytic degradation of important regulatory proteins. 40 In our experimental set-up, PKC inhibitors had no effect on monocyte TF activity. However, the possibility that different combinations of inhibitors may hide or exacerbate certain regulatory pathways, such as the PKC pathway, can not be excluded. From several other studies using alternate experimental systems, a PKC-dependent regulation of LPS-induced monocyte procoagulant activity (PCA) has been inferred. Typically, PKC agonists such as phorbol esters were found capable of stimulating PCA and as a second set of evidence, PKC inhibitors were able to abrogate LPS-stimulated PCA. 10, 11, 41 In contrast, we have never been able to see any effects of PKC inhibitors on LPS-induced TF in experiments performed with human whole blood. Our results are supported by the observation that the specific PKC inhibitor BIM did not inhibit LPS-induced PCA in murine peritoneal macrophages, 13 albeit staurosporine caused a partial inhibition of PCA.
Such varying and even contradictory results are probably very much related to the different degrees of cellular pre-activation inherent in the different set-ups. 42 Based on several observations, it has been suggested that isolation and culturing of cells inevitably lead to some cellular activation, one parameter of which is low-grade expression of TF. Thus, isolated monocytes as well as adherent monocytes do express TF mRNA, whereas monocytes in whole blood do not. 43 PKC is probably not directly involved in monocyte TF expression, but rather secondary effects stemming from activation of the PKC pathway somehow relate to the regulation of TF expression, possibly involving some common limiting cascade component(s). Thus activation of PKC enhances LPSinduced TF expression. 38 
CONCLUSIONS
These data provide evidence that PAF and TP receptors play key roles in the pathway(s) leading to LPS-stimulated TF activity. Some significant role for serine protease in the regulation of TF activity can also be inferred. Results from other studies, using TP -/mice or TP and PAF antagonists, further add to the notion that PAF and thromboxane A 2 are critically involved in inflammation, thrombosis and hemostasis. No evidence has emerged from our experiments that PKC, PLA 2 or 5-LO are of any significance for an efficient expression of monocyte TF in whole blood. Noticeably, it is possible that some of the inhibitors that were found to be without any effect in our whole-blood system may be effective in another experimental set-up such as cells in a plasma-free system. Thus, the complexity of whole blood may hide or exacerbate certain regulatory pathways. However, the major intention of our study was to reveal important pathways in LPSstimulated blood. The prospect of further identifying and mapping mediators involved in TF and TNF-a regulation holds considerable promise in finding ways to interfere constructively in relation to inflammation, sepsis, and thrombosis in circulating blood.
